Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Orthopaedic Surgery and Research
Published in: Journal of Orthopaedic Surgery and Research 1/2023

Open Access 01-12-2023 | Osteosarcoma | Research article

ARHGAP44-mediated regulation of the p53/C-myc/Cyclin D1 pathway in modulating the malignant biological behavior of osteosarcoma cells

Authors: Shizhe Li, Jiancheng Xue, He Zhang, Guanning Shang

Published in: Journal of Orthopaedic Surgery and Research | Issue 1/2023

Login to get access

Abstract

Objective

Osteosarcoma is a rare primary malignant tumor of the bone characterized by poor survival rates, owing to its unclear pathogenesis. Rho GTPase-activating protein 44 (ARHGAP44), which belongs to the Rho GTPase-activating protein family, has promising applications in the targeted therapy of tumors. Therefore, this study aimed to investigate the biological function of ARHGAP44 in osteosarcoma and its possible application as a therapeutic target.

Methods

The expression level of ARHGAP44 in osteosarcoma and its relationship with tumor prognosis were detected using Gene Expression Omnibus database analysis and immunohistochemical staining of clinical specimens. The cell model of ARHGAP44 knockdown was constructed, and the effects of this gene on the malignant biological behavior of osteosarcoma cells were investigated using CCK-8, clone formation, transwell invasion, wound healing, and flow cytometry assays. Western blotting was performed to detect the expression of ARHGAP44, p53, C-myc, and Cyclin D1 in osteosarcoma.

Results

Biogenic analysis showed that ARHGAP44 was highly expressed in osteosarcoma. This result was associated with poor tumor prognosis and negatively correlated with the expression of the tumor suppressor gene p53. Immunohistochemistry and western blotting revealed significantly upregulated expression of ARHGAP44 in osteosarcoma tissues. Additionally, Kaplan–Meier analysis of clinical specimens suggested that ARHGAP44 was negatively correlated with tumor prognosis. CCK-8, clone formation, transwell invasion, wound healing, and flow cytometry assays showed that downregulation of ARHGAP44 expression significantly reduced the malignant biological behavior of osteosarcoma cells. Furthermore, western blotting showed that the expression level of p53 in osteosarcoma cells was significantly increased after the downregulation of ARHGAP44 expression, whereas the expression of C-myc and Cyclin D1 was significantly decreased compared with that in the control group.

Conclusion

ARHGAP44 was highly expressed in osteosarcoma and was negatively correlated with its prognosis. The downregulation of ARHGAP44 expression reduced the malignant biological behavior of osteosarcoma cells. These findings suggest that the downregulation of ARHGAP44 expression inhibits the malignant progression of osteosarcoma by regulating the p53/C-myc/Cyclin D1 pathway, demonstrating the potential of ARHGAP44 as a therapeutic target for osteosarcoma.
Literature
1.
Meltzer PS, Helman LJ. New Horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385(22):2066–76.CrossRefPubMed
2.
Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020;21(18):6885.CrossRefPubMedPubMedCentral
3.
Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1–10.CrossRefPubMed
4.
Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201–17.CrossRefPubMed
5.
Li S, Zhang H, Liu J, et al. Targeted therapy for osteosarcoma: a review. J Cancer Res Clin Oncol. 2023;149(9):6785–97.CrossRefPubMed
6.
Goto N, Nishikawa M, Ito H, et al. Expression analyses of Rich2/Arhgap44, a rho family GTPase-activating protein, during mouse brain development. Dev Neurosci. 2023;45(1):19–26.CrossRefPubMed
7.
8.
Daino K, Imaoka T, Morioka T, et al. Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis. PLoS ONE. 2013;8(9):e74013.CrossRefPubMedPubMedCentral
9.
Zhang J, Yang C, Gong L, et al. RICH2, a potential tumor suppressor in hepatocellular carcinoma. Front Biosci. 2019;24(8):1363–76.CrossRef
10.
Hu S, Wang W. ARHGAP44 expression is associated with the metastasis of osteosarcoma and is a promising prognostic biomarker. J Orthop Res. 2023;41(6):1348–55.CrossRefPubMed
11.
Xu J, Jiao J, Xu W, et al. Mutant p53 promotes cell spreading and migration via ARHGAP44. Sci China Life Sci. 2017;60(9):1019–29.CrossRefPubMed
12.
Fritsche-Guenther R, Noske A, Ungethum U, et al. De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology. 2010;57(6):836–50.CrossRefPubMed
13.
Kelly AD, Haibe-Kains B, Janeway KA, et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013;5(1):2.CrossRefPubMedPubMedCentral
14.
15.
George S. Developments in systemic therapy for soft tissue and bone sarcomas. J Natl Compr Canc Netw. 2019;17(5.5):625–8.PubMed
16.
17.
Ouyang H, Luong P, Frödin M, et al. p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth. Oncogene. 2020;39(33):5570–87.CrossRefPubMedPubMedCentral
18.
Wang J, Qian J, Hu Y, et al. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun. 2014;5:4735.CrossRefPubMed
19.
Tian Q, Gao H, Zhou Y, et al. RICH1 inhibits breast cancer stem cell traits through activating kinases cascade of Hippo signaling by competing with Merlin for binding to Amot-p80. Cell Death Dis. 2022;13(1):71.CrossRefPubMedPubMedCentral
20.
Liu L, Xie D, Xie H, et al. ARHGAP10 inhibits the proliferation and metastasis of CRC cells via blocking the activity of RhoA/AKT signaling pathway. Onco Targets Ther. 2019;12:11507–16.CrossRefPubMedPubMedCentral
21.
Duffy MJ, Synnott NC, O’Grady S, et al. Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2022;79:58–67.CrossRefPubMed
22.
23.
24.
25.
Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8(3):282–8.CrossRefPubMed
26.
27.
Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2(10):3236.CrossRef
28.
Ramos-Garcia P, Gonzalez-Moles MA, Gonzalez-Ruiz L, et al. Clinicopathological significance of tumor cyclin D1 expression in oral cancer. Arch Oral Biol. 2019;99:177–82.CrossRefPubMed
29.
Sanjari M, Kordestani Z, Safavi M, et al. Enhanced expression of Cyclin D1 and C-myc, a prognostic factor and possible mechanism for recurrence of papillary thyroid carcinoma. Sci Rep. 2020;10(1):5100.CrossRefPubMedPubMedCentral
30.
Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94(12):1313–26.CrossRefPubMed
31.
Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25(4):398–406.CrossRefPubMed
32.
Liu Q, Wang Z, Zhou X, et al. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b. Cell Cycle. 2019;18(23):3325–36.CrossRefPubMedPubMedCentral
33.
Oyang L, Ouyang L, Yang L, et al. LPLUNC1 reduces glycolysis in nasopharyngeal carcinoma cells through the PHB1-p53/c-Myc axis. Cancer Sci. 2023;114(3):870–84.CrossRefPubMed
34.
Yenmis G, Besli N, Yaprak Sarac E, et al. Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism. Turk J Med Sci. 2021;51(2):826–34.CrossRefPubMedPubMedCentral
Metadata
Title
ARHGAP44-mediated regulation of the p53/C-myc/Cyclin D1 pathway in modulating the malignant biological behavior of osteosarcoma cells
Authors
Shizhe Li
Jiancheng Xue
He Zhang
Guanning Shang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Orthopaedic Surgery and Research / Issue 1/2023
Electronic ISSN: 1749-799X
DOI
https://doi.org/10.1186/s13018-023-04406-z

Other articles of this Issue 1/2023

Journal of Orthopaedic Surgery and Research 1/2023 Go to the issue

Research article

Docking site complications analysis of Ilizarov bone transport technique in the treatment of tibial bone defects

Research article

Giant cell tumors of the distal ulna: long-term recurrence rate and functional outcomes of en bloc resection versus curettage in a multicenter study

Systematic Review

Efficacy of acupuncture combined with active exercise training in improving pain and function of knee osteoarthritis individuals: a systematic review and meta-analysis

Research article

Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of Huang–Qi–Gui–Zhi–Wu–Wu decoction against deep vein thrombosis

Correspondence

Letter to the editor regarding “efficacy and safety of platelet-rich plasma combined with hyaluronic acid versus platelet-rich plasma alone for knee osteoarthritis: a systematic review and meta-analysis”

Research article

Increased lower limb length ratio in patients with patellar instability